Overview

Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to investigate the pharmacokinetics, safety and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (FDC) to those of preservative-free tafluprost 0.0015% and timolol 0.5% eye drops in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Santen Oy

Treatments:

Ophthalmic Solutions
Tetrahydrozoline
Timolol